News About: R&D
Eased responsibilities for challenging research failures
In order to promote R&D, the government will ease responsibilities for failures, but tighten restrictions on repeated wrongful uses of R&D expenses.
The Ministry of Trade, Industry and Energy(Minister Woon-Kyu Baek, ...
7 of 11 biosimilars approved in Korea were developed by Korean company
It was reported there were the total 11 biosimilar products approved in Korea, such as ‘Remsima 100mg,’ and 7 of them were developed by Korean pharmaceutical companies.
According to the Ministry of Food and Drug Safe...
Will the Pangyo era come with R&D center for small & medium pharmas?
Korea Pharmaceutical Ind. Coop. Chairman Yong-Jun Cho visited the Gyeonggi Provincial Government in the afternoon of the 4th and exchanged various opinions about small and medium pharmaceutical companies’ future direc...
How to evaluate and report safety for drug clinical trials?
A guideline for safety evaluation and report was prepared for pharmaceutical companies to use at drug clinical trials.
Pharmaceutical companies, clients for clinical trial, must have a person taking in charge of moni...
“352 Korean clinical trials were approved in 1st half of this year”
The Korea National Enterprise for Clinical Trials(Chairman Dong-Hyun Ji, KoNETC) revealed the pharmaceutical clinical trial registration status in the 1st half of 2017 at ClinicalTrials.gov, the world’s largest clinic...
Qurient acquires patent of Quinolinyloxyphenylsulfonamides related to cancer treatment
Qurient gave an official notice on the 12th that it acquired a patent of Quinolinyloxyphenylsulfonamides related to cancer treatment.
According to the company, the patent is about the core chemical structure of the a...
Subject of bioequivalence test will be extended to powder and granule
Bioequivalence tests, which have only been conducted on tablets, capsules and suppositories, will be extended to powder and granule products from November 2018.
The Ministry of Food and Drug Safety(MFDS) held the ‘Ci...
“It is not required to conduct animal studies for biosimilar development in some countries”
It was observed it was not required to conduct animal studies in the progress of developing biosimilars in some countries.
At the ‘Global Bio Conference’ at Intercontinental Coex Seoul on the 29th, Dr. Jian Wang(Heal...
Hanmi’s 3-sbustance combination drug containing Amosartan & rosuvastatin represented at EHS
2 case results of clinical trial for ‘Amosartan,’ a combination drug developed by Hanmi Pharm, were announced at the European Society of Hypertension(ESH).
Hanmi Pharm announced on the 20th that it presented a Phase ...
Hanmi Pharm presents study results of LAPSCOVERY at ADA
2 candidate substances of biologic applied with ‘LAPSCOVERY,’ Hanmi Pharm’s own platform technology, were revealed at the world’s largest diabetes association American Diabetes Association(ADA).
Hanmi Pharm(CEO Sae-C...
